Acute Myeloid Leukaemia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BioSight, GlycoMimetics, Sumitomo Pharma, Menarini, Telios, Kartos Therapeutics, ImmunoGen, Innovent Argenx

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 150+ key pharma and biotech companies are working on 150+ pipeline drugs in the Acute Myeloid Leukaemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Acute Myeloid Leukaemia Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Acute Myeloid Leukaemia Therapeutics Market.

The report provides a detailed description of the Acute Myeloid Leukaemia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Acute Myeloid Leukaemia Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Myeloid Leukaemia Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Acute Myeloid Leukaemia therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukaemia treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Acute Myeloid Leukaemia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Acute Myeloid Leukaemia treatment market.

Learn More about the Clinical and Commercial Development Activities in the Acute Myeloid Leukaemia Therapeutics Domain @
https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Myeloid Leukaemia Therapeutics Analysis
Over 150+ companies are actively involved in the development of therapies for Acute Myeloid Leukemia. Among these, GlycoMimetics stands out as a prominent player, with its Acute Myeloid Leukemia drug candidates advancing to the most advanced stage, namely Phase III.

Acute Myeloid Leukaemia Companies in the Therapeutics Market Include:
Some of the key companies in the Acute Myeloid Leukaemia Market include BioSight, GlycoMimetics, Sumitomo Pharma America, Inc., Menarini Group, Telios Pharma, Inc., Kartos Therapeutics, ImmunoGen, Inc., H3 Biomedicine Inc., Intellia Therapeutics, Chongqing Precision Biotech Co., Ltd., Innovent Biologics, Betta Pharmaceuticals Co., Ltd., Maxinovel Pty., Ltd., Argenx, Aptose Biosciences, ALX Oncology Inc., Novartis, Fujifilm Pharmaceuticals U.S.A., Inc., I-Mab Biopharma Co. Ltd., Akeso, Gilead Sciences, Kronos Bio, Celgene, Polaris Group, Ryvu Therapeutics SA, Kura Oncology, Inc., Sanofi, Amgen, BioTheryX, Inc., Arog Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Actinium Pharmaceuticals, Moleculin Biotech, and Karyopharm Therapeutics Inc., and many others.

Emerging and Marketed Acute Myeloid Leukaemia Therapies Covered in the Report Include:
• BST-236: BioSight
• Uproleselan: GlycoMimetics
• MK-0482: Merck Sharp & Dohme LLC
• Devimistat (CPI-613): Rafael Pharmaceuticals Inc.
• Crenolanib: Arog Pharmaceuticals
And Many Others

Get an in-depth Assessment of the Emerging Therapies and Acute Myeloid Leukaemia Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Acute Myeloid Leukaemia Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
The Acute Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type
Acute Myeloid Leukaemia Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Acute Myeloid Leukaemia Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Acute Myeloid Leukaemia Current Treatment Patterns
4. Acute Myeloid Leukaemia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Acute Myeloid Leukaemia Late-Stage Products (Phase-III)
7. Acute Myeloid Leukaemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Myeloid Leukaemia Discontinued Products
13. Acute Myeloid Leukaemia Product Profiles
14. Acute Myeloid Leukaemia Companies
15. Acute Myeloid Leukaemia Drugs
16. Dormant and Discontinued Products
17. Acute Myeloid Leukaemia Unmet Needs
18. Acute Myeloid Leukaemia Future Perspectives
19. Acute Myeloid Leukaemia Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.